gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Coagulation factor VII

clotting factor
Top mentioned proteins: CAN, HAD, AGE, FVIII, Thromboplastin
Papers on clotting factor
Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
Review
New
Carcao et al., Toronto, Canada. In Semin Thromb Hemost, Feb 2016
UNASSIGNED: Management of hemophilia has evolved significantly in the last century-from recognition of the causative mechanism in the 1950s to commercially available clotting factor concentrates in the 1960s.
Hemostatic Efficacy of Pathogen-Inactivated Blood Components.
Review
New
Ramsey, Chicago, United States. In Semin Thromb Hemost, Jan 2016
UNASSIGNED: Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities.
Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
Review
New
Monahan, Chapel Hill, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
For more than 3 decades, the scientific community has pursued gene correction of hemophilia, with the goal that an individual with congenitally deficient factor VIII or factor IX might synthesize adequate endogenous clotting factor to be relieved of burdensome repeated clotting factor infusions, as well as the emotional weight of continuous hemorrhage risk.
Coagulopathy in liver disease: a balancing act.
New
Kujovich, Portland, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
The fall in clotting factor levels is accompanied by a parallel fall in anticoagulant proteins.
Acquired bleeding disorders in the elderly.
New
Kruse-Jarres, Seattle, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow.
Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.
New
Migrants Working Group on behalf of COHERE in EuroCoord, In Lancet Hiv, Dec 2015
Individuals were eligible if enrolled in a cohort that collected information on geographical origin or ethnic origin from Jan 1, 1997, to March 19, 2013, aged 18-75 years, they had available information about sex, they were not infected perinatally or after the receipt of clotting factor concentrates, and were naive to combination antiretroviral therapy at cohort entry.
Improving care and treatment options for women and girls with bleeding disorders.
Review
New
Kulkarni, East Lansing, United States. In Eur J Haematol, Dec 2015
Treatment for HMB should consider patient wishes relating to preservation of fertility, and management options include hormonal measures, desmopressin, antifibrinolytics, platelet concentrate transfusions and clotting factor therapy.
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Review
Schutgens et al., Utrecht, Netherlands. In Cochrane Database Syst Rev, 2014
Secondary objectives were to assess if antifibrinolytic agents can replace or reduce the need for clotting factor concentrate therapy in people with haemophilia or Von Willebrand disease and to further establish the effects of these agents on bleeding in oral or dental procedures for each of these populations.
Is Hydroxyethyl Starch Irrelevant to Hemostasis in Patients Undergoing Liver Transplantation? - In vitro Analysis Based on Thromboelastometry.
Trzebicki et al., Warsaw, Poland. In Ann Transplant, 2014
Fibrinogen, malfunctioning in liver cirrhosis, is the earliest decreasing clotting factor while bleeding.
Association between physical activity and risk of bleeding in children with hemophilia.
Impact
Brown et al., Sydney, Australia. In Jama, 2012
The risk of bleeds associated with physical activity was estimated by contrasting exposure to physical activity in the 8 hours before the bleed with exposures in two 8-hour control windows, controlling for levels of clotting factor in the blood.
Modern haemophilia care.
Review
Impact
Shapiro et al., Malmö, Sweden. In Lancet, 2012
Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s.
Improving the Efficiency of Protein-Ligand Binding Free-Energy Calculations by System Truncation.
Ryde et al., Lund, Sweden. In J Chem Theory Comput, 2012
Ten inhibitors of the blood clotting factor Xa were studied, and the results were compared to an earlier study in which the protein was solvated in a periodic box, showing complete agreement between the two sets of calculations within statistical uncertainty.
Clotting factor gene polymorphisms and colorectal cancer risk.
Impact
Brenner et al., Heidelberg, Germany. In J Clin Oncol, 2011
Mainly small studies have addressed the association between clotting factor gene polymorphisms and the onset of colorectal cancer.
Nanoparticles for the delivery of genes and drugs to human hepatocytes.
Impact
Kuroda et al., Ibaraki, Japan. In Nat Biotechnol, 2003
When the gene encoding human clotting factor IX was transferred into the xenograft model using L particles, factor IX was produced at levels relevant to the treatment of hemophilia B. The yeast-derived L particle is free of viral genomes, highly specific to human liver cells and able to accommodate drugs as well as genes.
Protein-dependent ribozymes report molecular interactions in real time.
Impact
Famulok et al., Bonn, Germany. In Nat Biotechnol, 2002
A simple format switch allowed reliable monitoring of domain-specific interactions between the blood-clotting factor thrombin and its protein partners.
share on facebooktweetadd +1mail to friends